Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Scient Ind Res, Nicholas Piramal India LtdfiledCriticalCouncil Scient Ind Res
Priority to TNP2005000334ApriorityCriticalpatent/TNSN05334A1/en
Publication of TNSN05334A1publicationCriticalpatent/TNSN05334A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
A COMBINATION KIT FOR THE TREATMENT OF MALARIA CAUSED BY PLASMODIUM VIVAX (P.VIVAX)HAVING INDIVIDUAL DOSES OF AN ANTI-MALARIAL AGENT, 3-[ 1- [[4-[[(6-METHOXY-8-QUINOLINYL)AMINO]PENTYL]AMINO]ETHYLIDENE]-DIHYDRO-2(3H)-FURANONE (1) IN THE FORM OF CAPSULES ; INDIVIDUAL DOSES OF THE ANTI-MALARIAL AGENT, CHLOROQUINE IN THE FORM OF TABLETS ; AND INSTRUCTION MATERIAL FOR THE ADMINISTRATION OF THE TWO ANTI-MALARIAL DRUGS. THE COMBINATION KIT IS PARTICULARLY SUITED FOR A 6 DAYS TREATMENT REGIMEN WHERE THE TREATMENT IS RENDERED BY FIVE TABLETS CONTAINING 500 mg OF CHLOROQUINE PHOSPHATE (EQUIVALENT TO 300 mg BASE) , THREE TO BE TAKEN ON DAY ONE AND ONE EACH ON DAYS TWO AND THREE ; AND FIVE CAPSULES CONTAINING 25 mg OF 3-[1-[[4 [(6-METHOXY-8-QUINOLINYL)AMINO]PENTYL]AMINO]ETHYLIDENE]-DIHYDRO-2(3H)- FURANONE (1), ONE EACH TO BE TAKEN ON DAYS TWO SIX.
TNP2005000334A2005-12-282005-12-28A combination kit in the treatment of malaria
TNSN05334A1
(en)